M&T Bank Corp lowered its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 24.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,852 shares of the biopharmaceutical company’s stock after selling 1,549 shares during the quarter. M&T Bank Corp’s holdings in Regeneron Pharmaceuticals were worth $1,518,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in REGN. Dimensional Fund Advisors LP lifted its stake in shares of Regeneron Pharmaceuticals by 3.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 183,437 shares of the biopharmaceutical company’s stock valued at $68,499,000 after buying an additional 5,971 shares during the period. Geode Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock worth $402,138,000 after purchasing an additional 78,143 shares during the period. Moors & Cabot Inc. bought a new position in Regeneron Pharmaceuticals during the first quarter worth about $246,000. Robeco Institutional Asset Management B.V. lifted its stake in Regeneron Pharmaceuticals by 59.3% during the first quarter. Robeco Institutional Asset Management B.V. now owns 21,301 shares of the biopharmaceutical company’s stock worth $8,748,000 after purchasing an additional 7,931 shares during the period. Finally, Stevens Capital Management LP bought a new position in Regeneron Pharmaceuticals during the first quarter worth about $295,000. 66.55% of the stock is owned by institutional investors and hedge funds.
REGN has been the subject of a number of analyst reports. Leerink Swann set a $453.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 11th. TheStreet cut shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Wednesday, June 5th. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 18th. Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price target for the company in a research note on Wednesday, August 7th. Finally, BidaskClub cut shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 28th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $398.25.
Shares of Regeneron Pharmaceuticals stock opened at $292.00 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.88 and a quick ratio of 3.11. The firm has a market cap of $31.78 billion, a P/E ratio of 14.43, a P/E/G ratio of 1.32 and a beta of 1.13. The firm has a 50 day simple moving average of $297.74 and a 200 day simple moving average of $338.11. Regeneron Pharmaceuticals Inc has a fifty-two week low of $279.39 and a fifty-two week high of $442.00.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.60 by $0.69. The firm had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.45 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 19.22 EPS for the current year.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Percentage Decliners
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.